Keyword: European Society of Cardiology
AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too.
Pfizer and Bristol-Myers Squibb’s Eliquis has already secured a sizable lead over its rivals, and now its touting more competitor-topping data.
With a trial setback for its $5 billion CV hopeful in its way, Novartis is looking at the bright side—Entresto flopped, but it was a “narrow miss.”
Pfizer's tafamidis data may have impressed on Monday, but that doesn’t mean Alnylam and its newly approved Onpattro are out of the running.
At last year’s ESC meeting, J&J was touting data that put its clot-busting Xarelto on track for $1 billion-plus in additional sales. Not so this year.
Analysts are expecting Pfizer to spell out the benefits of its potential blockbuster drug to treat TTR-CM at ESC.
AstraZeneca has pegged big hopes on its clot-fighter Brilinta, and it's rolling out numbers designed to advance them. Will it work?
Cardiovascular drugs may not be the top field in terms of sales or market growth rate. But heart disease and related ailments remain the biggest cause of death in the U.S. We’ve put together this list as a state-of-the-market snapshot, coinciding with the European Society of Cardiology meeting this week.
Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?
Will Entresto be the megablockbuster that was expected? Early numbers say it isn't so. But Novartis has reason to believe, according to some talk at ESC this week.